DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Univasc (Moexipril Hydrochloride) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, univasc® should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

 

UNIVASC SUMMARY

univasc® (moexipril hydrochloride), the hydrochloride salt of moexipril, has the empirical formula C27H34N2O7 ·HCl and a molecular weight of 535. It is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat.

univasc® is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics.

In using univasc®, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that univasc® does not have a similar risk (see WARNINGS).

In considering use of univasc®, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS, Angioedema).
See all Univasc indications & dosage >>

UNIVASC NEWS HIGHLIGHTS

Published Studies Related to Univasc (Moexipril)

Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. [2002.01]

Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Moexipril as Antihypertensive Drug After Menopause. [1999.05]

Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. [1999.05]

Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. [1998.09.20]

Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril. [1998.09]

more >>

Clinical Trials Related to Univasc (Moexipril)

Moexipril for Primary Biliary Cirrhosis [Completed]

Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension [Completed]

more >>

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008